Top

Published in:

01-05-2014 | Research Article

Expression and clinical significance of BIRC6 in human epithelial ovarian cancer

Authors: Lin Wang, Yan-Jie Chen, Jun Hou, Ya-Yun Wang, Wen-Qing Tang, Xi-Zhong Shen, Rui-Qin Tu

Published in: Tumor Biology | Issue 5/2014

Abstract

Baculoviral IAP repeat containing 6 (BIRC6), an unusually large member of the IAP family, may play an important role in oncogenesis. The aim of this study was to assess the value of BIRC6 in predicting tumor recurrence after curative resection in epithelial ovarian cancer (EOC) patients. In this study, the differences of BIRC6 expression in four paired EOC and normal tissue were performed by Western blot, and expression of BIRC6 protein was analyzed in 100 clinicopathologically characterized EOC cases from those who underwent curative resection between 2003 and 2011 by immunohistochemistry. Kaplan-Meier survival estimates and log-rank tests were used to assess the prognostic significance. It was found that BIRC6 expression was higher in the carcinoma tissue than in normal control tissue at protein level by Western blot. There was a significant difference of BIRC6 expression in patients categorized according to tumor differentiation (p = 0.016). Univariate analyses and multivariate analyses revealed that BIRC6 was an independent significant predictor for overall survival and disease-free survival. A prognostic significance of BIRC6 was also found by Kaplan-Meier method. The expression of BIRC6 in the cytoplasm is associated with EOC differentiation and may be a novel predictor for poor prognosis of EOC patients after curative resection.

Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA: a cancer journal for clinicians. 2012;62(1):10–29. doi:10.3322/caac.20138.

Wright JD, Shah M, Mathew L, Burke WM, Culhane J, Goldman N, et al. Fertility preservation in young women with epithelial ovarian cancer. Cancer. 2009;115(18):4118–26. doi:10.1002/cncr.24461.CrossRefPubMed

Anderson GL. Ovarian cancer biomarker screening: still too early to tell. Women’s Health (Lond Engl). 2010;6(4):487–90. doi:10.2217/whe.10.33.CrossRef

Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57–70.CrossRefPubMed

Wong RS. Apoptosis in cancer: from pathogenesis to treatment. Journal of experimental & clinical cancer research : CR. 2011;30:87. doi:10.1186/1756-9966-30-87.CrossRefPubMedCentral

Hauser HP, Bardroff M, Pyrowolakis G, Jentsch S. A giant ubiquitin-conjugating enzyme related to IAP apoptosis inhibitors. The Journal of cell biology. 1998;141(6):1415–22.CrossRefPubMedPubMedCentral

Chen Z, Naito M, Hori S, Mashima T, Yamori T, Tsuruo T. A human IAP-family gene, Apollon, expressed in human brain cancer cells. Biochemical and biophysical research communications. 1999;264(3):847–54. doi:10.1006/bbrc.1999.1585.CrossRefPubMed

Bianchini M, Levy E, Zucchini C, Pinski V, Macagno C, De Sanctis P, et al. Comparative study of gene expression by cDNA microarray in human colorectal cancer tissues and normal mucosa. International journal of oncology. 2006;29(1):83–94.PubMed

Sung KW, Choi J, Hwang YK, Lee SJ, Kim HJ, Lee SH, et al. Overexpression of Apollon, an antiapoptotic protein, is associated with poor prognosis in childhood de novo acute myeloid leukemia. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007;13(17):5109–14. doi:10.1158/1078-0432.CCR-07-0693.CrossRef

10.

Lopergolo A, Pennati M, Gandellini P, Orlotti NI, Poma P, Daidone MG, et al. Apollon gene silencing induces apoptosis in breast cancer cells through p53 stabilisation and caspase-3 activation. British journal of cancer. 2009;100(5):739–46. doi:10.1038/sj.bjc.6604927.CrossRefPubMedPubMedCentral

11.

Van Houdt WJ, Emmink BL, Pham TV, Piersma SR, Verheem A, Vries RG et al. Comparative proteomics of colon cancer stem cells and differentiated tumor cells identifies BIRC6 as a potential therapeutic target. Molecular & cellular proteomics: MCP. 2011;10(12):M111 011353. doi:10.1074/mcp.M111.011353.

12.

Ismail EA, Mahmoud HM, Tawfik LM, Habashy DM, Adly AA, El-Sherif NH, et al. BIRC6/Apollon gene expression in childhood acute leukemia: impact on therapeutic response and prognosis. European journal of haematology. 2012;88(2):118–27. doi:10.1111/j.1600-0609.2011.01734.x.CrossRefPubMed

13.

Lamers F, Schild L, Koster J, Speleman F, Ora I, Westerhout EM, et al. Identification of BIRC6 as a novel intervention target for neuroblastoma therapy. BMC cancer. 2012;12:285. doi:10.1186/1471-2407-12-285.CrossRefPubMedPubMedCentral

14.

Low CG, Luk IS, Lin D, Fazli L, Yang K, Xu Y, et al. BIRC6 protein, an inhibitor of apoptosis: role in survival of human prostate cancer cells. PloS one. 2013;8(2):e55837. doi:10.1371/journal.pone.0055837.CrossRefPubMedPubMedCentral

15.

Ren J, Shi M, Liu R, Yang QH, Johnson T, Skarnes WC, et al. The Birc6 (Bruce) gene regulates p53 and the mitochondrial pathway of apoptosis and is essential for mouse embryonic development. Proc Natl Acad Sci U S A. 2005;102(3):565–70. doi:10.1073/pnas.0408744102.CrossRefPubMedPubMedCentral

16.

Qiu XB, Goldberg AL. The membrane-associated inhibitor of apoptosis protein, BRUCE/Apollon, antagonizes both the precursor and mature forms of Smac and caspase-9. The Journal of biological chemistry. 2005;280(1):174–82. doi:10.1074/jbc.M411430200.CrossRefPubMed

17.

Qiu XB, Markant SL, Yuan J, Goldberg AL. Nrdp1-mediated degradation of the gigantic IAP, BRUCE, is a novel pathway for triggering apoptosis. The EMBO journal. 2004;23(4):800–10. doi:10.1038/sj.emboj.7600075.CrossRefPubMedPubMedCentral

18.

Pohl C, Jentsch S. Final stages of cytokinesis and midbody ring formation are controlled by BRUCE. Cell. 2008;132(5):832–45. doi:10.1016/j.cell.2008.01.012.CrossRefPubMed

19.

Chu L, Gu J, Sun L, Qian Q, Qian C, Liu X. Oncolytic adenovirus-mediated shRNA against Apollon inhibits tumor cell growth and enhances antitumor effect of 5-fluorouracil. Gene therapy. 2008;15(7):484–94. doi:10.1038/gt.2008.6.CrossRefPubMed

20.

Hao Y, Sekine K, Kawabata A, Nakamura H, Ishioka T, Ohata H, et al. Apollon ubiquitinates SMAC and caspase-9, and has an essential cytoprotection function. Nature cell biology. 2004;6(9):849–60. doi:10.1038/ncb1159.CrossRefPubMed

21.

Dong X, Lin D, Low C, Vucic EA, English JC, Yee J, et al. Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2013;8(2):161–70. doi:10.1097/JTO.0b013e31827d5237.CrossRef

22.

Chen Y, Fu D, Xi J, Ji Z, Liu T, Ma Y, et al. Expression and clinical significance of UCH37 in human esophageal squamous cell carcinoma. Digestive diseases and sciences. 2012;57(9):2310–7. doi:10.1007/s10620-012-2181-9.CrossRefPubMed

Title: Expression and clinical significance of BIRC6 in human epithelial ovarian cancer
Authors: Lin Wang
Yan-Jie Chen
Jun Hou
Ya-Yun Wang
Wen-Qing Tang
Xi-Zhong Shen
Rui-Qin Tu
Publication date: 01-05-2014
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 5/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-014-1641-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2014

MTHFR genetic polymorphisms may contribute to the risk of chronic myelogenous leukemia in adults: a meta-analysis of 12 genetic association studies

Genistein exhibits anti-cancer effects via down-regulating FoxM1 in H446 small-cell lung cancer cells

RETRACTED ARTICLE: The prognosis and clinicopathology of CXCR4 in gastric cancer patients: a meta-analysis

Endoglin, VEGF, and its receptors in predicting metastases in endometrial carcinoma

ChIP-seq predicted estrogen receptor biding sites in human breast cancer cell line MCF7

Is there any diagnostic value of serum protease-activated receptor-1 (PAR1) levels on determination of epithelial ovarian carcinoma?

Keynote webinar | Spotlight on antibody–drug conjugates in cancer